Skip to main content

Pa. Court Considers Risperdal Statute of Limitations Dispute

Pa. Court Considers Risperdal Statute of Limitations Dispute

Pa. Court Considers Risperdal Statute of Limitations Dispute

Introduction

On Thursday, May 16, the Pennsylvania Supreme Court examined the level of public awareness regarding the dangers of Risperdal, which can put potential plaintiffs on notice to investigate their claims.

Two men filed a lawsuit in 2014 against the antipsychotic drug alleging Janssen Pharmaceuticals failed to warn the side effects of the drug. The following year, however, Philadelphia Common Pleas Court Judge Arnold New dismissed their lawsuits determining that the Risperdal statute of limitations had begun tolling in August 2009, based on the framework of newspaper articles, medical literature, and attorney advertisements available at that time. The Court’s final decision will decide the fate of thousands of similar claims currently pending in Philadelphia. If the state’s Supreme Court upholds the statute of limitations ruling, about 40% of those claims would be dismissed.

There are around 7,000 gynecomastia lawsuits pending in the Pennsylvania mass tort program. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775, presided by Honorable William Highberger) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!